Medical/Pharmaceuticals

NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...

2025-11-21 13:46 1000

Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

* The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, marking an important milestone in its global clinical dev...

2025-11-21 12:01 1034

Dimora Medical Reaffirms Long-Term Commitment to Pressure Injury Patients on Worldwide Pressure Injury Prevention Day

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Observed annually on the third Thursday of November each year, Worldwide Pressure Injury Prevention Day serves as a global reminder of the urgent need to prevent pressure injuries, also known as pressure ulcers or bedsores, among vulnerable populations. Est...

2025-11-21 11:14 700

PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting

IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted fo...

2025-11-20 23:12 1335

HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases

* Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH...

2025-11-20 22:30 888

ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone

BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a$4.6M grant from the California Institute for Regenerative Medicine (CIRM)

2025-11-20 22:00 795

GENPRIME ACCELERATES GLOBAL GROWTH WITH FERTILITY CENTRE LAUNCHES IN SINGAPORE AND MANILA

The Singapore and New York-headquartered network of clinics expands its Southeast Asia presence, addressing global family-building challenges with technology and empathy NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Rhea Fertility, the reproductive health platform headquartered inSingapore and New Yor...

2025-11-20 22:00 873

Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer

* The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. * The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 cli...

2025-11-20 18:52 1222

Clarity Eye Centre Brings SILK™ Laser Eye Technology to Hong Kong

HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients inHong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that po...

2025-11-20 17:34 1158

Smartee Deepens Its Strategy for Central Asia and Russia in 2025

SHANGHAI, Nov. 20, 2025 /PRNewswire/ -- Smartee Denti-Technology is reinforcing its international footprint with a focused strategy inCentral Asia and Russia for 2025, cementing its position as a global leader in clear aligner and digital orthodontic technologies. This year, Smartee showcased it...

2025-11-20 13:53 777

Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide

Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed * Adoption of Remplir™ among Australian urologists is accelerating, with ~100 surgeries conducted by surgeons nationwide. * This promising new applicatio...

2025-11-20 13:52 688

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

DURHAM, N.C. and SEOUL, South Korea, Nov. 20, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation i...

2025-11-20 13:01 1461

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs

SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...

2025-11-20 10:56 908

WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry

WuXi AppTec sets new benchmarks in strategic execution and technological advancement, further strengthening its ability to support innovators worldwide as they deliver breakthrough medicines for patients. SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan

2025-11-20 10:00 745

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] wo...

2025-11-20 03:00 1131

Dimora Medical Supports HS Connect Empower Workshop to Promote Science-Based Care for Hidradenitis Suppurativa Patients

NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Patient-centered nonprofit organization HS Connect recently hosted the Empower HS: Knowledge and Advocacy Workshop, an educational event designed to help individuals living with Hidradenitis Suppurativa (HS) and their caregivers gain the knowledge and confi...

2025-11-20 01:48 1025

NABR: CITES Standing Committee Issues Assessment of Long-Tailed Macaque Monkey Breeding Practices

WASHINGTON, Nov. 20, 2025 /PRNewswire/ -- The Standing Committee of CITES, an international body responsible for monitoring trade in animal species, announced the results of its review of animal breeding practices inCambodia, thankingCambodia for providing extensive data and relying on science. T...

2025-11-20 01:33 927

Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein and anti...

2025-11-19 22:17 896

Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery

Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...

2025-11-19 20:08 650

The Rise of Advanced Maternal Age IVF: BaseCare Medical'-B(2170.HK) AI "Undisturbed Culture" Empowers Intelligent Assisted Reproduction

SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Data from the keynote report at the 18th Annual Conference of the Chinese Society of Reproductive Medicine (CSRM2025), held fromNovember 12th to 15th, indicates that the average treatment age for women undergoing IVF inChina has risen to 33.6 years, h...

2025-11-19 19:50 745
1 ... 78910111213 ... 645